Sage Capital Advisors llc Takes $213,000 Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Sage Capital Advisors llc purchased a new position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 523 shares of the pharmaceutical company’s stock, valued at approximately $213,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VRTX. LSV Asset Management raised its stake in Vertex Pharmaceuticals by 206.3% during the 1st quarter. LSV Asset Management now owns 4,751 shares of the pharmaceutical company’s stock worth $1,240,000 after acquiring an additional 3,200 shares in the last quarter. Synovus Financial Corp raised its stake in Vertex Pharmaceuticals by 9.6% during the 1st quarter. Synovus Financial Corp now owns 6,737 shares of the pharmaceutical company’s stock worth $1,759,000 after acquiring an additional 590 shares in the last quarter. Cibc World Market Inc. raised its stake in Vertex Pharmaceuticals by 69.4% during the 1st quarter. Cibc World Market Inc. now owns 6,622 shares of the pharmaceutical company’s stock worth $1,728,000 after acquiring an additional 2,713 shares in the last quarter. Sei Investments Co. raised its stake in Vertex Pharmaceuticals by 28.4% during the 1st quarter. Sei Investments Co. now owns 44,090 shares of the pharmaceutical company’s stock worth $11,756,000 after acquiring an additional 9,761 shares in the last quarter. Finally, Cetera Investment Advisers raised its stake in Vertex Pharmaceuticals by 4.0% during the 1st quarter. Cetera Investment Advisers now owns 14,114 shares of the pharmaceutical company’s stock worth $3,683,000 after acquiring an additional 544 shares in the last quarter. 90.77% of the stock is currently owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Trading Down 0.3 %

Shares of VRTX opened at $407.69 on Monday. The company has a current ratio of 3.99, a quick ratio of 3.78 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average is $424.97 and its two-hundred day moving average is $387.53. Vertex Pharmaceuticals Incorporated has a twelve month low of $290.66 and a twelve month high of $448.40. The firm has a market capitalization of $105.31 billion, a P/E ratio of 29.35, a PEG ratio of 2.25 and a beta of 0.35.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last issued its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 earnings per share for the quarter, topping the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company had revenue of $2.52 billion for the quarter, compared to analyst estimates of $2.50 billion. During the same period in the prior year, the business posted $3.33 earnings per share. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research reports. HC Wainwright raised their price objective on shares of Vertex Pharmaceuticals from $397.00 to $457.00 and gave the stock a “buy” rating in a research report on Tuesday, February 6th. Canaccord Genuity Group downgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “sell” rating and raised their price objective for the stock from $332.00 to $379.00 in a research report on Wednesday, January 24th. Robert W. Baird downgraded shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective on the stock. in a research report on Wednesday, January 31st. Canaccord Genuity Group reissued a “sell” rating and set a $379.00 price objective (up from $332.00) on shares of Vertex Pharmaceuticals in a research report on Wednesday, January 24th. Finally, Wolfe Research initiated coverage on shares of Vertex Pharmaceuticals in a research report on Thursday, February 15th. They set an “outperform” rating and a $515.00 price objective on the stock. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Vertex Pharmaceuticals presently has a consensus rating of “Hold” and a consensus price target of $417.27.

Get Our Latest Report on Vertex Pharmaceuticals

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $420.24, for a total value of $1,354,013.28. Following the sale, the executive vice president now owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the transaction, the executive vice president now owns 74,364 shares of the company’s stock, valued at $31,250,727.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Jeffrey M. Leiden sold 6,648 shares of the company’s stock in a transaction that occurred on Monday, January 8th. The shares were sold at an average price of $419.07, for a total transaction of $2,785,977.36. Following the transaction, the chairman now directly owns 2,423 shares in the company, valued at approximately $1,015,406.61. The disclosure for this sale can be found here. Insiders have sold 19,029 shares of company stock valued at $7,989,227 over the last quarter. Corporate insiders own 0.40% of the company’s stock.

Vertex Pharmaceuticals Profile

(Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read More

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXFree Report).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.